Shattuck Labs IncNASDAQ:STTK
- LAST PRICE3.8700
- TODAY'S CHANGE (%)0.1500 (4.0323%)
- Bid / Lots3.5300/ 5
- Ask / Lots3.9000/ 3
- Open / Previous Close3.7700 / 3.7200
- Day Range
- 52 Week Range
- Volume170,077
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STTK |
|---|---|---|
| 09:32 ET | 749 | 3.77 |
| 09:38 ET | 100 | 3.8 |
| 09:39 ET | 500 | 3.81 |
| 09:45 ET | 100 | 3.81 |
| 09:50 ET | 671 | 3.83 |
| 09:54 ET | 1238 | 3.805 |
| 09:57 ET | 200 | 3.84 |
| 10:01 ET | 100 | 3.85 |
| 10:03 ET | 200 | 3.85 |
| 10:06 ET | 100 | 3.86 |
| 10:08 ET | 100 | 3.86 |
| 10:10 ET | 200 | 3.83 |
| 10:12 ET | 100 | 3.85 |
| 10:14 ET | 282 | 3.82 |
| 10:21 ET | 200 | 3.82 |
| 10:26 ET | 100 | 3.83 |
| 10:28 ET | 300 | 3.82 |
| 10:32 ET | 200 | 3.83 |
| 10:37 ET | 200 | 3.84 |
| 10:39 ET | 200 | 3.85 |
| 10:44 ET | 300 | 3.87 |
| 10:46 ET | 300 | 3.865 |
| 10:50 ET | 500 | 3.88 |
| 10:51 ET | 200 | 3.88 |
| 10:53 ET | 2060 | 3.89 |
| 10:55 ET | 100 | 3.9 |
| 11:00 ET | 1400 | 3.86 |
| 11:02 ET | 100 | 3.86 |
| 11:06 ET | 1293 | 3.86 |
| 11:09 ET | 1187 | 3.9 |
| 11:11 ET | 525 | 3.9 |
| 11:18 ET | 148 | 3.9199 |
| 11:20 ET | 100 | 3.93 |
| 11:22 ET | 300 | 3.91 |
| 11:24 ET | 100 | 3.93 |
| 11:26 ET | 500 | 3.93 |
| 11:40 ET | 759 | 3.9 |
| 11:42 ET | 300 | 3.93 |
| 11:44 ET | 618 | 3.91 |
| 11:51 ET | 200 | 3.89 |
| 11:56 ET | 100 | 3.92 |
| 11:58 ET | 252 | 3.92 |
| 12:03 ET | 300 | 3.895 |
| 12:05 ET | 400 | 3.87 |
| 12:12 ET | 100 | 3.86 |
| 12:16 ET | 100 | 3.86 |
| 12:20 ET | 229 | 3.86 |
| 12:30 ET | 100 | 3.85 |
| 12:43 ET | 6000 | 3.836 |
| 12:50 ET | 200 | 3.835 |
| 12:52 ET | 300 | 3.85 |
| 12:54 ET | 100 | 3.86 |
| 01:06 ET | 200 | 3.87 |
| 01:12 ET | 300 | 3.86 |
| 01:26 ET | 300 | 3.86 |
| 01:39 ET | 1286 | 3.8613 |
| 01:46 ET | 1287 | 3.88 |
| 02:04 ET | 127 | 3.8782 |
| 02:08 ET | 100 | 3.87 |
| 02:13 ET | 100 | 3.88 |
| 02:20 ET | 200 | 3.87 |
| 02:27 ET | 1159 | 3.86 |
| 02:29 ET | 100 | 3.86 |
| 02:31 ET | 1298 | 3.85 |
| 02:33 ET | 300 | 3.84 |
| 02:38 ET | 400 | 3.85 |
| 02:51 ET | 600 | 3.86 |
| 02:54 ET | 100 | 3.86 |
| 02:58 ET | 100 | 3.85 |
| 03:02 ET | 200 | 3.85 |
| 03:05 ET | 385 | 3.85 |
| 03:07 ET | 5000 | 3.852 |
| 03:09 ET | 100 | 3.845 |
| 03:12 ET | 151 | 3.8479 |
| 03:14 ET | 600 | 3.87 |
| 03:27 ET | 185 | 3.875 |
| 03:32 ET | 7000 | 3.87 |
| 03:34 ET | 2794 | 3.88 |
| 03:36 ET | 887 | 3.87 |
| 03:38 ET | 300 | 3.86 |
| 03:39 ET | 400 | 3.88 |
| 03:45 ET | 300 | 3.86 |
| 03:48 ET | 200 | 3.85 |
| 03:50 ET | 1684 | 3.85 |
| 03:52 ET | 1234 | 3.87 |
| 03:54 ET | 2300 | 3.85 |
| 03:56 ET | 100 | 3.85 |
| 03:57 ET | 2529 | 3.86 |
| 03:59 ET | 11212 | 3.87 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shattuck Labs Inc | 177.5M | -2.1x | --- |
Atossa Therapeutics Inc | 174.8M | -7.3x | --- |
DiaMedica Therapeutics Inc | 183.8M | -8.0x | --- |
Greenwich Lifesciences Inc | 188.2M | -17.8x | --- |
Ventyx Biosciences Inc | 166.8M | -0.8x | --- |
Galectin Therapeutics Inc | 165.0M | -3.5x | --- |
Company Information
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Contact Information
- Headquarters
- 500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701
- Phone
- 512-900-4690
- Fax
- ---
Executives
- Independent Chairman of the Board
- George Golumbeski
- Chief Executive Officer, Co-Founder, Director
- Taylor Schreiber
- Chief Financial Officer
- Andrew Neill
- General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
- Stephen Stout
- Chief Business Officer
- Casi Deyoung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $177.5M |
|---|---|
Revenue (TTM) | $4.1M |
Shares Outstanding | 47.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-1.85 |
Book Value | $3.06 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 43.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,195.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
